169 related articles for article (PubMed ID: 14643169)
21. Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?
Tennant RC; Erin EM; Barnes PJ; Hansel TT
Curr Opin Pharmacol; 2003 Jun; 3(3):270-6. PubMed ID: 12810191
[TBL] [Abstract][Full Text] [Related]
22. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
23. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
24. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
[TBL] [Abstract][Full Text] [Related]
25. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
26. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
[TBL] [Abstract][Full Text] [Related]
27. Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD.
Yildiz BP; Bayraktaroglu M; Gunen H
Curr Med Res Opin; 2019 Dec; 35(12):2187-2196. PubMed ID: 31397184
[No Abstract] [Full Text] [Related]
28. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
[TBL] [Abstract][Full Text] [Related]
29. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.
ZuWallack AR; ZuWallack RL
Expert Opin Pharmacother; 2004 Aug; 5(8):1827-35. PubMed ID: 15264997
[TBL] [Abstract][Full Text] [Related]
30. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
31. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD.
Cazzola M; Matera MG; Di Perna E; Califano C; D'Amato M; Mazzarella G
Respir Med; 1999 Dec; 93(12):909-11. PubMed ID: 10653054
[TBL] [Abstract][Full Text] [Related]
32. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis.
Wang J; Jin D; Zuo P; Wang T; Xu Y; Xiong W
Respirology; 2011 Feb; 16(2):350-8. PubMed ID: 21138499
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
34. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
35. Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD.
Meyer T; Reitmeir P; Brand P; Herpich C; Sommerer K; Schulze A; Scheuch G; Newman S
Respir Med; 2011 Jun; 105(6):900-6. PubMed ID: 21397483
[TBL] [Abstract][Full Text] [Related]
36. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
37. Is sustained pharmacologic lung volume reduction now possible in COPD?
O'Donnell DE
Chest; 2006 Mar; 129(3):501-3. PubMed ID: 16537841
[No Abstract] [Full Text] [Related]
38. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
39. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
[TBL] [Abstract][Full Text] [Related]
40. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease.
Cramer JA; Bradley-Kennedy C; Scalera A
Can Respir J; 2007; 14(1):25-9. PubMed ID: 17315055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
